All patients with ALL, patients with osteosarcoma (n = 6/7), and all patients with medulloblastoma showed reduced CP and/or AP functionality at several time points following chemotherapy, whereas patients with Ewing sarcoma or germ cell tumors had no significant reduction in complement activation upon treatment for their solid tumor (Figure 4). This evidence concerns the gene DHCR7-DT and medulloblastoma.